Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer

Rong Ma, Heng Xu, Jianzhong Wu, Ashok Kumar Sharma, Shan Bai, Boying Dun, Changwen Jing, Haixia Cao, Zhuo Wang, Jin-Xiong She, Jifeng Feng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lung cancer is one of the most prevalent cancers and has very poor treatment outcome. Biomarkers useful for screening and assessing early therapeutic response may significantly improve the therapeutic outcome but are still lacking. In this study, serum samples from 218 non-small cell lung cancer (NSCLC) patients, 34 small cell lung cancer (SCLC) patients and 171 matched healthy controls from China were analyzed for 11 proteins using the Luminex multiplex assay. Eight of the 11 proteins (OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF) are significantly elevated in NSCLC and SCLC (p = 10-5-10-59). At the individual protein level, OPN has the best diagnostic value for NSCLC (AUC = 0.92), two acute phase proteins (SAA and CRP) have AUC near 0.83, while CEA and CYFRA21.1 also possess good AUC (0.81 and 0.77, respectively). More importantly, several three-protein combinations that contain OPN and CEA plus one of four proteins (CRP, SAA, CYFRA21.1 or NSE) have excellent diagnostic potential for NSCLC (AUC = 0.96). Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy. Therapeutic response index (TRI) computed with 3-5 proteins suggests that approximately 25% of the NSCLC patients respond well to the therapy and TRI is significantly correlated with pre-treatment protein levels. Our data suggest that therapeutic response in NSCLC patients can be effectively measured but personalized biomarkers may be needed to monitor different subsets of patients.

Original languageEnglish (US)
Pages (from-to)18901-18913
Number of pages13
JournalOncotarget
Volume8
Issue number12
DOIs
StatePublished - Jan 1 2017

Fingerprint

Blood Proteins
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Proteins
Area Under Curve
Therapeutics
Small Cell Lung Carcinoma
Biomarkers
Acute-Phase Proteins
Platinum
China
Drug Therapy
Serum
Neoplasms

Keywords

  • Biomarkers
  • Inflammation
  • NSCLC
  • Therapeutic response
  • Tumor antigens

ASJC Scopus subject areas

  • Oncology

Cite this

Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer. / Ma, Rong; Xu, Heng; Wu, Jianzhong; Sharma, Ashok Kumar; Bai, Shan; Dun, Boying; Jing, Changwen; Cao, Haixia; Wang, Zhuo; She, Jin-Xiong; Feng, Jifeng.

In: Oncotarget, Vol. 8, No. 12, 01.01.2017, p. 18901-18913.

Research output: Contribution to journalArticle

Ma, Rong ; Xu, Heng ; Wu, Jianzhong ; Sharma, Ashok Kumar ; Bai, Shan ; Dun, Boying ; Jing, Changwen ; Cao, Haixia ; Wang, Zhuo ; She, Jin-Xiong ; Feng, Jifeng. / Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer. In: Oncotarget. 2017 ; Vol. 8, No. 12. pp. 18901-18913.
@article{3a830454f4fb4a6291a11ed1579aa29d,
title = "Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer",
abstract = "Lung cancer is one of the most prevalent cancers and has very poor treatment outcome. Biomarkers useful for screening and assessing early therapeutic response may significantly improve the therapeutic outcome but are still lacking. In this study, serum samples from 218 non-small cell lung cancer (NSCLC) patients, 34 small cell lung cancer (SCLC) patients and 171 matched healthy controls from China were analyzed for 11 proteins using the Luminex multiplex assay. Eight of the 11 proteins (OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF) are significantly elevated in NSCLC and SCLC (p = 10-5-10-59). At the individual protein level, OPN has the best diagnostic value for NSCLC (AUC = 0.92), two acute phase proteins (SAA and CRP) have AUC near 0.83, while CEA and CYFRA21.1 also possess good AUC (0.81 and 0.77, respectively). More importantly, several three-protein combinations that contain OPN and CEA plus one of four proteins (CRP, SAA, CYFRA21.1 or NSE) have excellent diagnostic potential for NSCLC (AUC = 0.96). Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy. Therapeutic response index (TRI) computed with 3-5 proteins suggests that approximately 25{\%} of the NSCLC patients respond well to the therapy and TRI is significantly correlated with pre-treatment protein levels. Our data suggest that therapeutic response in NSCLC patients can be effectively measured but personalized biomarkers may be needed to monitor different subsets of patients.",
keywords = "Biomarkers, Inflammation, NSCLC, Therapeutic response, Tumor antigens",
author = "Rong Ma and Heng Xu and Jianzhong Wu and Sharma, {Ashok Kumar} and Shan Bai and Boying Dun and Changwen Jing and Haixia Cao and Zhuo Wang and Jin-Xiong She and Jifeng Feng",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14782",
language = "English (US)",
volume = "8",
pages = "18901--18913",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

TY - JOUR

T1 - Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer

AU - Ma, Rong

AU - Xu, Heng

AU - Wu, Jianzhong

AU - Sharma, Ashok Kumar

AU - Bai, Shan

AU - Dun, Boying

AU - Jing, Changwen

AU - Cao, Haixia

AU - Wang, Zhuo

AU - She, Jin-Xiong

AU - Feng, Jifeng

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Lung cancer is one of the most prevalent cancers and has very poor treatment outcome. Biomarkers useful for screening and assessing early therapeutic response may significantly improve the therapeutic outcome but are still lacking. In this study, serum samples from 218 non-small cell lung cancer (NSCLC) patients, 34 small cell lung cancer (SCLC) patients and 171 matched healthy controls from China were analyzed for 11 proteins using the Luminex multiplex assay. Eight of the 11 proteins (OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF) are significantly elevated in NSCLC and SCLC (p = 10-5-10-59). At the individual protein level, OPN has the best diagnostic value for NSCLC (AUC = 0.92), two acute phase proteins (SAA and CRP) have AUC near 0.83, while CEA and CYFRA21.1 also possess good AUC (0.81 and 0.77, respectively). More importantly, several three-protein combinations that contain OPN and CEA plus one of four proteins (CRP, SAA, CYFRA21.1 or NSE) have excellent diagnostic potential for NSCLC (AUC = 0.96). Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy. Therapeutic response index (TRI) computed with 3-5 proteins suggests that approximately 25% of the NSCLC patients respond well to the therapy and TRI is significantly correlated with pre-treatment protein levels. Our data suggest that therapeutic response in NSCLC patients can be effectively measured but personalized biomarkers may be needed to monitor different subsets of patients.

AB - Lung cancer is one of the most prevalent cancers and has very poor treatment outcome. Biomarkers useful for screening and assessing early therapeutic response may significantly improve the therapeutic outcome but are still lacking. In this study, serum samples from 218 non-small cell lung cancer (NSCLC) patients, 34 small cell lung cancer (SCLC) patients and 171 matched healthy controls from China were analyzed for 11 proteins using the Luminex multiplex assay. Eight of the 11 proteins (OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF) are significantly elevated in NSCLC and SCLC (p = 10-5-10-59). At the individual protein level, OPN has the best diagnostic value for NSCLC (AUC = 0.92), two acute phase proteins (SAA and CRP) have AUC near 0.83, while CEA and CYFRA21.1 also possess good AUC (0.81 and 0.77, respectively). More importantly, several three-protein combinations that contain OPN and CEA plus one of four proteins (CRP, SAA, CYFRA21.1 or NSE) have excellent diagnostic potential for NSCLC (AUC = 0.96). Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy. Therapeutic response index (TRI) computed with 3-5 proteins suggests that approximately 25% of the NSCLC patients respond well to the therapy and TRI is significantly correlated with pre-treatment protein levels. Our data suggest that therapeutic response in NSCLC patients can be effectively measured but personalized biomarkers may be needed to monitor different subsets of patients.

KW - Biomarkers

KW - Inflammation

KW - NSCLC

KW - Therapeutic response

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=85015783536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015783536&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14782

DO - 10.18632/oncotarget.14782

M3 - Article

VL - 8

SP - 18901

EP - 18913

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -